Early Breast Cancer Trialists' Collaborative G. et al.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Lancet. 378: 1707-1716

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

Lancet. 383: 2127-2135

Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.

J Clin Oncol. 35: 3222-3229

Molecular heterogeneity in breast cancer: State of the science and implications for patient care.

Semin Cell Dev Biol. 64: 65-72

Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy.

Journal of Clinical Oncology. 29: 3885-3891

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

New England Journal of Medicine. 375: 717-729

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

New England Journal of Medicine. 379: 111-121

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 31: 2382-2387

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Lancet Oncol. 16: 266-273

Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment.

International Journal of Radiation Oncology, Biology, Physics. 89: 392-398

Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy.

Annals of Surgical Oncology. 17: 2899-2908

Impact of Postmastectomy Radiation on Locoregional Recurrence in Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated With Modern Systemic Therapy.

International Journal of Radiation Oncology, Biology, Physics. 83: e577-e581

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Practical Radiation Oncology. 6: e219-e234

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

The Lancet Oncology. 14: 1086-1094

Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer.

New England Journal of Medicine. 362: 513-520

Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

Pract Radiat Oncol. 8: 145-152

Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France.

J Clin Oncol. 15: 963-968

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

Lancet Oncol. 16: 47-56

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

Lancet Oncol. 21: 685-698

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

Journal of Clinical Oncology. 38: 3261-3272

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.

The Lancet. 390: 1048-1060

Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.

Journal of Clinical Oncology. ()

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.

The Lancet. 394: 2165-2172

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.

The Lancet. 394: 2155-2164

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

The Lancet. 395: 1613-1626

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

J Natl Cancer Inst. 97: 116-126

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.

The Lancet Oncology. 20: 352-360

Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.

Journal of Clinical Oncology. 35: 2037-2043

5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.

International Journal of Radiation Oncology, Biology, Physics. 107: 694-700

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer.

New England Journal of Medicine. 351: 2817-2826

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 28: 1677-1683

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.

J Natl Cancer Inst. 109

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.

JAMA Oncol. 6: 505-511

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.

Breast Cancer Research and Treatment. 148: 599-613

Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort.

Clin Cancer Res. 20: 5272-5280

Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients.

Clinical Cancer Research. 15: 4181

Search for a gene expression signature of breast cancer local recurrence in young women.

Clin Cancer Res. 18: 1704-1715

Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer.

Clin Cancer Res. 21: 3667-3677

A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences.

International Journal of Radiation Oncology*Biology*Physics. 108: 686-696

Prediction of radiation sensitivity using a gene expression classifier.

Cancer research. 65: 7169-7176

Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform.

International journal of radiation oncology, biology, physics. 75: 497-505

A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation.

International Journal of Radiation Oncology, Biology, Physics. 75: 489-496

The radiosensitivity index predicts for overall survival in glioblastoma.

Oncotarget. 6: 34414-34422

Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy.

International Journal of Radiation Oncology, Biology, Physics. 106: 496-502

A Molecular Signature of Radiosensitivity (RSI) is an RT-specific Biomarker in Prostate Cancer.

International Journal of Radiation Oncology, Biology, Physics. 90: S157

Radiosensensitivity Index Shows Promise for Predicting Outcomes With Adjuvant Radiation in Resected Pancreatic Cancer Patients.

International Journal of Radiation Oncology, Biology, Physics. 90: S174

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.

Lancet Oncol. 18: 202-211

Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.

Int J Radiat Oncol Biol Phys. 93: 631-638

Validation of a radiosensitivity molecular signature in breast cancer.

Clin Cancer Res. 18: 5134-5143

Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management.

EBioMedicine. 47: 163-169Validation of a radiosensitivity molecular signature in breast cancer. 18. Clinical cancer research: an official journal of the American Association for Cancer Research, : 5134-5143

Biologic Subtypes of Primary Breast Tumors Exhibit Differences in the Radiosensitivity Index.

International Journal of Radiation Oncology, Biology, Physics. 102: e601-e602

Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.

International journal of radiation oncology, biology, physics. 93: 631-638

PV-0048 The Radiosensitivity Index (RSI) predicts for outcomes in triple negative breast cancer.

Radiotherapy and Oncology. 133: S17-S18

Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.

Breast Cancer Res. 20: 64

Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.

Clinical Cancer Research. 24: 4754

The linear quadratic model: usage, interpretation and challenges.

Physics in Medicine & Biology. 64 ()

The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction.

Semin Radiat Oncol. 18: 234-239

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.

Journal of Clinical Oncology. 37: 3340-3349

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Journal of Clinical Oncology. 33: 3938-3944

Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS).

Breast Cancer Research and Treatment. 143: 343-350

RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation.

Journal of Clinical Oncology. 33: 709-715

A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

J Natl Cancer Inst. 105: 701-710

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.

Breast cancer research and treatment. 152: 389-398

Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.

Journal of the National Cancer Institute. 109: djw256

21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma in Situ.

J Natl Cancer Inst.

A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk.

Clinical Cancer Research. 24: 5895

Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy.

Clinical Cancer Research. 26: 4054Royston P. Altman D.G. Sauerbrei W.

Dichotomizing continuous predictors in multiple regression: a bad idea.

Stat Med. 25: 127-141

The cost of dichotomising continuous variables.

BMJ (Clinical research ed.). 332: 1080

Analysis by Categorizing or Dichotomizing Continuous Variables Is Inadvisable: An Example from the Natural History of Unruptured Aneurysms.

American Journal of Neuroradiology. 32: 437

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.

J Clin Oncol. 20: 4141-4149

Tamoxifen with or without Breast Irradiation in Women 50 Years of Age or Older with Early Breast Cancer.

New England Journal of Medicine. 351: 963-970

Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.

Journal of Clinical Oncology. 32 (): 1008

Oncotype Score as a Predictor of Local-Regional Recurrence in Early Stage Breast Cancer (BC).

International Journal of Radiation Oncology, Biology, Physics. 99: S54-S55

Current and future role of neoadjuvant therapy for breast cancer.

The Breast. 23: 526-537

Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.

Ann Oncol. 31: 61-71

Orien..

Oncology Issues. 31: 62-66

Establishment of a Radiogenomics Consortium.

International Journal of Radiation Oncology, Biology, Physics. 76: 1295-1296

National Institutes of Health Funding in Radiation Oncology: A Snapshot.

International Journal of Radiation Oncology, Biology, Physics. 86: 234-240